Phase II/Pharmacodynamic Study of the gamma-secretase Inhibitor RO4929097 in Patients Who Have Recently Completed Front-line Chemotherapy for Advanced Non-Small Cell Lung Cancer

Trial Profile

Phase II/Pharmacodynamic Study of the gamma-secretase Inhibitor RO4929097 in Patients Who Have Recently Completed Front-line Chemotherapy for Advanced Non-Small Cell Lung Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2015

At a glance

  • Drugs RG 4733 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Nov 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 21 Dec 2012 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top